Cell Biology Quiz: Oncogenes Vs Tumor Suppressors
19 questions · exam conditions
0:00
Oncogenes Vs Tumor SuppressorsQuestion 1 of 19

A researcher observes that a particular gene, when overexpressed in normal cells, causes them to lose contact inhibition and continue dividing beyond normal density limits. However, when this same gene is deleted from cancer cells, the cells continue to proliferate uncontrollably. Based on this experimental evidence, what is the most likely classification of this gene?

This gene functions as an oncogene because its overexpression promotes uncontrolled cell division
This gene functions as a tumor suppressor because its deletion fails to prevent cancer cell proliferation
This gene exhibits characteristics of both oncogenes and tumor suppressors depending on cellular context
This gene is likely a proto-oncogene that has undergone mutation to become constitutively active
This gene cannot be classified without additional information about its normal cellular function
← Back to quizzes

Cell Biology Quiz

Cell Biology Quiz: Oncogenes Vs Tumor Suppressors

Practice Oncogenes Vs Tumor Suppressors in Cell Biology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Oncogenes Vs Tumor Suppressors, giving you a quick way to practice the rules, question types, and explanations that matter most for Cell Biology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A researcher observes that a particular gene, when overexpressed in normal cells, causes them to lose contact inhibition and continue dividing beyond normal density limits. However, when this same gene is deleted from cancer cells, the cells continue to proliferate uncontrollably. Based on this experimental evidence, what is the most likely classification of this gene?

  1. This gene functions as an oncogene because its overexpression promotes uncontrolled cell division (correct answer)
  2. This gene functions as a tumor suppressor because its deletion fails to prevent cancer cell proliferation
  3. This gene exhibits characteristics of both oncogenes and tumor suppressors depending on cellular context
  4. This gene is likely a proto-oncogene that has undergone mutation to become constitutively active
  5. This gene cannot be classified without additional information about its normal cellular function
Explanation: When analyzing gene function in cancer biology, you need to distinguish between oncogenes and tumor suppressors based on how their activity affects cell division control. The key is examining what happens when the gene is overexpressed versus when it's deleted or inactivated. Let's work through this experimental evidence systematically. When this gene is overexpressed in normal cells, it causes loss of contact inhibition and uncontrolled division - classic hallmarks of malignant transformation. This directly demonstrates that increased activity of this gene promotes cancer-like behavior, which is the defining characteristic of an oncogene. Answer A correctly identifies this as an oncogene because overexpression leads to uncontrolled proliferation. The experimental evidence clearly shows that increased gene activity drives cancerous behavior. Answer B misinterprets the deletion experiment. The fact that deleting this gene from already-transformed cancer cells doesn't stop their proliferation doesn't make it a tumor suppressor - cancer cells have multiple mutations and don't depend on any single gene for continued growth. Answer C suggests dual functionality, but the evidence doesn't support this. The gene consistently promotes cell division when active; the deletion experiment simply shows that cancer cells have acquired independence from normal growth controls. Answer D focuses on proto-oncogene mutation, but the question asks about gene classification based on the observed effects, not mutational status. Remember: oncogenes are "gas pedals" for cell division - when they're overactive, cells divide uncontrollably. Tumor suppressors are "brakes" - when they're lost, normal growth control fails. Focus on what increased gene activity does to determine classification.

Question 2

A novel cancer therapy involves introducing a vector that increases expression of protein Z in tumor cells. In clinical trials, this treatment successfully shrinks tumors that have lost protein Z function, but causes rapid tumor growth in cancers where protein Z is already overexpressed. What does this therapeutic response pattern reveal about protein Z's normal role in cell cycle control?

  1. Protein Z is an oncogene whose loss of function contributes to some cancers while overexpression drives others
  2. Protein Z is a tumor suppressor whose restoration can reverse cancer progression in deficient cells (correct answer)
  3. Protein Z is a cell cycle checkpoint protein whose function depends on proper dosage control
  4. Protein Z is a proto-oncogene that becomes oncogenic only when overexpressed beyond normal levels
  5. Protein Z exhibits tissue-specific functions as either an oncogene or tumor suppressor
Explanation: When analyzing cancer therapies that affect tumor growth differently depending on the cancer type, you're examining how proteins function in normal cell cycle control and what happens when that control is disrupted. The key insight here lies in the therapeutic response pattern: introducing more protein Z helps tumors that have lost protein Z function (shrinks tumors) but worsens tumors where protein Z is already overexpressed (accelerates growth). This bidirectional effect reveals that protein Z normally acts as a tumor suppressor. Tumor suppressors are protective proteins that prevent uncontrolled cell division. When they're lost or non-functional, cells can become cancerous. Restoring tumor suppressor function through gene therapy can reverse this process, which explains why the treatment shrinks tumors lacking protein Z. Choice A incorrectly identifies protein Z as an oncogene. Oncogenes promote cell growth, so increasing their expression would accelerate tumor growth in all cases, not selectively help deficient tumors. Choice C suggests protein Z is a checkpoint protein requiring precise dosage, but checkpoint proteins typically show toxicity rather than tumor promotion when overexpressed. Choice D describes a proto-oncogene, but the treatment's success in shrinking deficient tumors contradicts this classification since adding more of an oncogenic protein wouldn't be therapeutically beneficial. For cell biology questions about cancer therapeutics, focus on the functional distinction: tumor suppressors are "brakes" on cell division (losing them causes cancer, restoring them helps), while oncogenes are "accelerators" (gaining them causes cancer). The therapeutic response pattern will always reveal which category the protein belongs to.

Question 3

Researchers studying cellular transformation create two cell lines: Line A has a gain-of-function mutation in gene P, while Line B has a loss-of-function mutation in gene Q. Both lines show similar phenotypes: increased proliferation, resistance to apoptosis, and anchorage-independent growth. However, Line A's phenotype can be rescued by expressing a dominant-negative version of gene P, while Line B's phenotype requires expressing wild-type gene Q for rescue. What can be concluded about genes P and Q?

  1. Both gene P and gene Q are oncogenes, but they act through different cellular pathways
  2. Both gene P and gene Q are tumor suppressors, but gene P shows dominant effects
  3. Gene P is an oncogene because dominant-negative rescue works, while gene Q is a tumor suppressor (correct answer)
  4. Gene P is a tumor suppressor because it can be inhibited, while gene Q is an oncogene
  5. The genes represent different classes of cell cycle regulators with opposing normal functions
Explanation: When analyzing cellular transformation experiments, you need to distinguish between oncogenes and tumor suppressors based on how mutations affect cell behavior and how that behavior can be rescued. Gene P shows oncogene characteristics: a gain-of-function mutation causes transformation, and expressing a dominant-negative version (which interferes with normal protein function) rescues the phenotype. This pattern indicates that excessive P activity drives transformation, so blocking it restores normal behavior. Gene Q shows tumor suppressor characteristics: a loss-of-function mutation causes transformation, and only wild-type Q expression can rescue the phenotype. This indicates that Q normally prevents transformation, so losing its function allows uncontrolled growth. Answer A is incorrect because both genes aren't oncogenes—gene Q requires functional protein for rescue, indicating it's a tumor suppressor. Answer B is wrong because both genes aren't tumor suppressors—gene P's gain-of-function mutation and dominant-negative rescue clearly indicate oncogene behavior. Answer D reverses the correct classifications and misinterprets the rescue experiments—the ability to inhibit gene P actually confirms it's an oncogene, not a tumor suppressor. The key study tip: Remember that oncogenes cause cancer when they're overactive (gain-of-function), while tumor suppressors cause cancer when they're lost (loss-of-function). The rescue method tells the story: dominant-negative rescue indicates oncogene behavior (blocking the bad actor), while wild-type replacement indicates tumor suppressor behavior (restoring the missing guardian).

Question 4

A pharmaceutical company develops two experimental cancer drugs: Drug Alpha inhibits the kinase activity of protein R, while Drug Beta activates the transcriptional activity of protein S. In preclinical trials, both drugs show anti-tumor effects, with Drug Alpha preventing tumor growth and Drug Beta causing tumor regression. What do these therapeutic mechanisms suggest about the normal cellular functions of proteins R and S?

  1. Protein R is a tumor suppressor kinase, while protein S is an oncogenic transcription factor
  2. Protein R is an oncogenic kinase, while protein S is a tumor suppressor transcription factor (correct answer)
  3. Both proteins are oncogenes that promote cancer through different mechanisms
  4. Both proteins are tumor suppressors whose activities are enhanced by the respective drugs
  5. Protein R and protein S represent different phases of cell cycle control mechanisms
Explanation: When analyzing drug mechanisms and their therapeutic effects, you need to work backwards from the observed outcomes to deduce the normal protein functions. The key insight is understanding how inhibiting versus activating different proteins leads to anti-cancer effects. Drug Alpha inhibits protein R's kinase activity and prevents tumor growth. This means that normally, protein R must promote cell division and tumor formation - making it an oncogenic kinase. By blocking its activity, the drug stops cancer progression. Drug Beta activates protein S's transcriptional activity and causes tumor regression (shrinkage). This indicates protein S normally acts as a brake on cell growth - it's a tumor suppressor transcription factor that likely activates genes controlling cell cycle arrest or apoptosis. Answer B correctly identifies protein R as an oncogenic kinase and protein S as a tumor suppressor transcription factor. Answer A reverses these roles, incorrectly suggesting that inhibiting a tumor suppressor would prevent cancer (it would actually promote it). Answer C wrongly categorizes both as oncogenes - if protein S were oncogenic, activating it would worsen cancer, not cause regression. Answer D incorrectly labels both as tumor suppressors, which doesn't explain why inhibiting protein R (rather than activating it) produces therapeutic benefit. Remember this logical framework: if inhibiting a protein fights cancer, that protein likely promotes cancer (oncogene). If activating a protein fights cancer, that protein likely suppresses cancer normally (tumor suppressor). This reverse-engineering approach is crucial for therapeutic mechanism questions.

Question 5

Two cancer cell lines are treated with different experimental therapies. Cell line 1 is treated with a drug that reduces expression of gene W, resulting in decreased proliferation and increased apoptosis. Cell line 2 is treated with a drug that increases expression of gene V, also resulting in decreased proliferation and increased apoptosis. Both cell lines show similar responses to their respective treatments. What can be inferred about the normal functions of genes W and V in cancer development?

  1. Both gene W and gene V are oncogenes that promote cancer when expressed at abnormal levels
  2. Both gene W and gene V are tumor suppressors that protect against cancer development
  3. Gene W is an oncogene whose reduction inhibits cancer, while gene V is a tumor suppressor whose increase inhibits cancer (correct answer)
  4. Gene W is a tumor suppressor whose reduction inhibits cancer, while gene V is an oncogene whose increase inhibits cancer
  5. Both genes regulate apoptosis but through different mechanisms that cannot be classified as oncogenes or tumor suppressors
Explanation: When you encounter questions about cancer genetics, focus on how different genes respond to therapeutic interventions. The key insight is that reducing cancer requires either turning down oncogenes (cancer-promoting genes) or turning up tumor suppressors (cancer-protecting genes). Let's analyze what happens with each treatment. Cell line 1 receives a drug that reduces gene W expression, leading to decreased proliferation and increased apoptosis—both desirable anti-cancer effects. This tells you that gene W normally promotes cancer growth, making it an oncogene. When you reduce an oncogene's activity, cancer cells behave better. Cell line 2 receives a drug that increases gene V expression, also producing beneficial anti-cancer effects. This means gene V normally protects against cancer, making it a tumor suppressor. When you boost a tumor suppressor's activity, cancer cells are more likely to undergo apoptosis and stop proliferating. Answer choice C correctly identifies this pattern: gene W is an oncogene (reduced expression helps) while gene V is a tumor suppressor (increased expression helps). Choice A incorrectly labels both as oncogenes—if gene V were an oncogene, increasing its expression would worsen cancer, not improve it. Choice B incorrectly labels both as tumor suppressors—if gene W were a tumor suppressor, reducing its expression would worsen cancer. Choice D reverses the gene identities completely. Remember this principle: effective cancer therapy either silences oncogenes or amplifies tumor suppressors. The direction of the therapeutic intervention (increase vs. decrease) reveals the gene's normal role.

Question 6

A research team investigates the effects of gene silencing in different cellular contexts. When gene H is silenced in normal primary cells, the cells show enhanced proliferation and reduced senescence. However, when gene H is silenced in immortalized cancer cell lines, the same cells show decreased proliferation and increased apoptosis. What does this context-dependent response pattern suggest about gene H's cellular role?

  1. Gene H is an oncogene whose effects depend on the cellular transformation status
  2. Gene H is a tumor suppressor that functions differently in normal versus cancer cells
  3. Gene H has dual functions as both an oncogene and tumor suppressor
  4. Gene H is a cell cycle regulator whose function is corrupted in cancer cells (correct answer)
  5. Gene H represents a context-dependent gene whose classification cannot be determined from this data
Explanation: When you encounter questions about genes showing opposite effects in different cell types, focus on how cellular context shapes gene function rather than assuming fixed roles. Gene H demonstrates context-dependent regulation typical of cell cycle control genes. In normal primary cells, silencing gene H enhances proliferation and reduces senescence, suggesting it normally acts as a brake on cell division. However, in immortalized cancer cells, silencing the same gene decreases proliferation and increases apoptosis, indicating it has become essential for cancer cell survival. This flip in function occurs because cancer cells have rewired their regulatory networks, making them dependent on genes that normally restrict growth in healthy cells. Answer D correctly identifies gene H as a cell cycle regulator whose function becomes corrupted in the cancer context. Answer A is incorrect because oncogenes typically promote cell growth in both normal and cancer contexts when activated, not silenced. Answer B mischaracterizes the pattern - a tumor suppressor would show consistent growth-promoting effects when silenced across both cell types. Answer C suggests gene H simultaneously acts as both an oncogene and tumor suppressor, but the data shows context-dependent function of a single regulatory role, not dual inherent functions. The key insight is that cancer fundamentally alters cellular dependencies - genes that normally suppress division can become essential for cancer cell survival due to oncogene addiction and altered signaling pathways. Remember: When genes show opposite effects in normal versus cancer cells, think about corrupted regulation rather than inherently dual functions. Cancer cells often become addicted to dysregulated versions of normal growth controls.

Question 7

Comparative genomic analysis reveals that gene K undergoes chromosomal translocations in certain leukemias, creating fusion proteins with enhanced activity. In solid tumors, the same gene K shows promoter hypermethylation leading to silencing. Both alteration patterns are associated with poor patient prognosis. How should gene K be classified based on these genomic alterations?

  1. Gene K is an oncogene in leukemias but a tumor suppressor in solid tumors (correct answer)
  2. Gene K is a tumor suppressor whose silencing or overactivation both contribute to cancer
  3. Gene K is an oncogene whose activation by translocation and inactivation by methylation both promote cancer
  4. Gene K cannot be classified as it shows contradictory patterns in different cancer types
  5. Gene K is a proto-oncogene that becomes oncogenic through different mechanisms in different cancers
Explanation: When analyzing genes involved in cancer, you need to understand that the same gene can function differently depending on the context and type of alteration. The key is determining whether the cancer-promoting effect comes from gain of function (oncogene behavior) or loss of function (tumor suppressor behavior). In leukemias, gene K undergoes chromosomal translocations that create fusion proteins with enhanced activity. This gain-of-function mechanism is classic oncogene behavior—the gene's overactivation drives cancer progression. In solid tumors, gene K shows promoter hypermethylation leading to silencing. This loss-of-function mechanism is characteristic of tumor suppressor genes—the gene normally prevents cancer, but when silenced, it can no longer fulfill this protective role. Answer A correctly identifies this dual nature: gene K acts as an oncogene in leukemias (activation promotes cancer) and as a tumor suppressor in solid tumors (inactivation promotes cancer). Answer B incorrectly suggests gene K is always a tumor suppressor. True tumor suppressors are harmful when inactivated, not when overactivated. Answer C incorrectly labels gene K as always an oncogene. True oncogenes are harmful when activated, not when inactivated through methylation. Answer D is wrong because genes can indeed show context-dependent behavior—this isn't contradictory but rather reflects the complex nature of cancer biology. Study tip: Remember that some genes can function as either oncogenes or tumor suppressors depending on the cancer type and mechanism of alteration. Focus on whether the cancer-driving effect comes from gaining or losing the gene's normal function.

Question 8

In studying familial cancer predisposition, geneticists observe that mutations in gene L show autosomal dominant inheritance for cancer risk, but the cancer-associated mutations are actually loss-of-function alleles. Paradoxically, individuals who inherit one mutant copy have increased cancer risk despite retaining one normal copy of gene L. What mechanism best explains this inheritance pattern?

  1. Gene L is an oncogene where loss-of-function mutations create dominant-negative effects
  2. Gene L is a tumor suppressor where heterozygous loss creates haploinsufficiency for cancer protection
  3. Gene L is a tumor suppressor following the classic two-hit model where the first hit predisposes to cancer (correct answer)
  4. Gene L exhibits genomic imprinting where only one allele is normally active
  5. Gene L is a DNA repair gene where heterozygous mutations cause immediate transformation
Explanation: When you encounter questions about familial cancer syndromes with seemingly paradoxical inheritance patterns, focus on distinguishing between predisposition and actual cancer development in tumor suppressor genes. The key insight here is understanding Knudson's two-hit hypothesis for tumor suppressors. Gene L is a tumor suppressor that normally prevents cancer when functioning properly. In familial cancer syndromes, individuals inherit one defective copy (the "first hit") in every cell of their body. While they still have one normal copy providing some protection, they're now just one additional mutation away from losing all tumor suppressor function in any given cell. When the remaining normal copy is lost or inactivated in a somatic cell (the "second hit"), that cell loses cancer protection entirely and can become malignant. This explains why the inheritance appears dominant for cancer risk—inheriting just one mutant copy dramatically increases cancer probability—even though the actual mechanism requires loss of both functional copies. Option A is incorrect because oncogenes promote cancer when activated, not when they lose function, and this describes a tumor suppressor scenario. Option B misrepresents the mechanism—while there is heterozygous loss, the increased cancer risk isn't due to haploinsufficiency of the remaining copy, but rather the predisposition to lose that remaining function. Option D is wrong because genomic imprinting involves parent-of-origin effects, not the two-hit mechanism described here. Remember: familial cancer syndromes typically involve tumor suppressors where inheriting one "broken" copy sets up vulnerability for the classic two-hit process.

Question 9

A novel therapeutic approach involves delivering microRNAs that specifically downregulate gene expression. In clinical trials, microRNA-X (which targets gene A) shows anti-tumor activity, while microRNA-Y (which targets gene B) actually accelerates tumor progression. Both microRNAs effectively reduce their target gene expression by >90%. What do these therapeutic outcomes reveal about genes A and B?

  1. Gene A is a tumor suppressor and gene B is an oncogene, both responding predictably to reduced expression
  2. Gene A is an oncogene whose downregulation inhibits tumors, while gene B is a tumor suppressor whose loss accelerates cancer (correct answer)
  3. Both genes are oncogenes, but gene B has additional tumor suppressor functions
  4. Both genes are tumor suppressors, but gene A has additional oncogenic functions
  5. Gene A and gene B represent competing pathways where their relative expression determines cancer outcome
Explanation: When evaluating therapeutic outcomes from microRNA treatments, you need to understand how different gene types respond to downregulation. The key is working backwards from the clinical results to determine what type of genes are being targeted. MicroRNA-X reduces gene A expression by >90% and shows anti-tumor activity. This means that when gene A is silenced, tumors are inhibited. This pattern indicates gene A must be an oncogene - a gene that promotes cancer when active. Reducing an oncogene's expression logically leads to reduced tumor growth. MicroRNA-Y reduces gene B expression by >90% but accelerates tumor progression. When gene B is silenced, tumors grow faster. This suggests gene B normally acts as a tumor suppressor - a gene that prevents cancer when functioning properly. Losing tumor suppressor function removes the brakes on cell division, allowing accelerated tumor growth. Answer B correctly identifies this relationship: gene A is an oncogene (downregulation helps) and gene B is a tumor suppressor (downregulation harms). Answer A reverses the gene classifications. Answer C incorrectly suggests both are oncogenes, which can't explain why silencing gene B accelerates tumors. Answer D incorrectly suggests both are tumor suppressors, which can't explain why silencing gene A inhibits tumors. Study tip: Remember that oncogenes are like a car's accelerator (removing them slows cancer), while tumor suppressors are like brakes (removing them speeds up cancer). Always match the therapeutic outcome to the expected behavior of each gene type.

Question 10

In a longitudinal study of cancer progression, researchers track genetic changes over time in patient biopsies. They observe that gene E shows progressive amplification (2x → 4x → 8x copies) that correlates with increasing tumor grade, while gene F shows progressive deletion (heterozygous loss → homozygous loss) that also correlates with increasing tumor grade. What do these progressive genetic changes indicate about the roles of genes E and F in cancer development?

  1. Both genes are oncogenes whose progressive alteration drives tumor progression
  2. Both genes are tumor suppressors whose progressive loss drives tumor progression
  3. Gene E is an oncogene whose amplification drives progression, while gene F is a tumor suppressor whose loss drives progression (correct answer)
  4. Gene E is a tumor suppressor whose amplification drives progression, while gene F is an oncogene whose loss drives progression
  5. Both genes represent dosage-sensitive regulators whose imbalance drives cancer regardless of their normal functions
Explanation: When analyzing genetic changes in cancer progression, you need to distinguish between oncogenes and tumor suppressors based on how their alteration affects tumor development. Oncogenes promote cell growth when activated or amplified, while tumor suppressors normally prevent cancer and contribute to tumor development when lost or inactivated. Gene E shows progressive amplification (increasing copy numbers from 2x to 8x) that correlates with worsening tumor grade. This pattern indicates Gene E is an oncogene—more copies lead to increased oncogenic protein production, driving more aggressive cancer behavior. Gene F shows progressive deletion (from heterozygous to homozygous loss) also correlating with tumor progression. This indicates Gene F is a tumor suppressor—its progressive loss removes protective mechanisms that normally prevent cancer development. Choice A incorrectly classifies Gene F as an oncogene, but oncogenes don't drive cancer through deletion—they require activation or amplification. Choice B incorrectly classifies Gene E as a tumor suppressor, but tumor suppressors don't drive cancer through amplification—they cause problems when lost. Choice D reverses both classifications entirely, suggesting tumor suppressors drive cancer through amplification and oncogenes through loss, which contradicts fundamental cancer biology principles. Choice C correctly identifies the opposing roles: Gene E as an oncogene (amplification drives progression) and Gene F as a tumor suppressor (loss drives progression). Remember this pattern: amplification/overexpression suggests oncogene, while deletion/loss suggests tumor suppressor. The direction of genetic change tells you the gene's normal function in cancer prevention or promotion.

Question 11

A biotech company develops a gene therapy vector that delivers a modified version of gene G to cancer cells. The modified gene G produces a protein that retains its normal enzymatic activity but lacks its regulatory domains. In preclinical studies, this therapy causes cancer cell death specifically in tumors that have wild-type gene G, but has no effect on tumors that already have mutated gene G. What does this selective therapeutic effect indicate about gene G's normal function?

  1. Gene G is an oncogene whose unregulated activity is toxic to cells (correct answer)
  2. Gene G is a tumor suppressor whose enzymatic activity kills cancer cells
  3. Gene G is a cell cycle checkpoint gene whose dysregulation causes apoptosis
  4. Gene G is a DNA repair enzyme whose overactivity is selectively toxic to cancer cells
  5. Gene G exhibits tumor suppressor function that is enhanced when regulatory controls are removed
Explanation: When you encounter gene therapy questions, focus on how the therapeutic effect reveals the gene's normal cellular role. The key insight here is understanding what happens when regulatory control is removed from a protein. The therapy delivers a modified gene G that produces protein with normal enzymatic activity but no regulatory domains. This creates an "always on" version of the protein. The selective toxicity pattern—killing cells with wild-type gene G but not those with already-mutated gene G—tells us that uncontrolled activity of this protein is lethal to cells. Answer A is correct because this pattern indicates gene G is normally an oncogene. Oncogenes promote cell growth and division, but they require tight regulatory control. When you remove the regulatory domains, the protein becomes constitutively active, driving excessive cell proliferation or other growth signals that become toxic. Cancer cells with wild-type gene G still respond to this unregulated signal and die from the overwhelming activity. Answer B is wrong because tumor suppressors normally prevent cancer—their increased activity would be beneficial, not selectively toxic. Answer C incorrectly suggests checkpoint gene dysregulation causes apoptosis, but checkpoint genes typically arrest cell division rather than directly causing death. Answer D mischaracterizes the mechanism—while DNA repair enzyme overactivity might be problematic, the selective toxicity pattern specifically points to growth-promoting genes (oncogenes) rather than repair genes. Remember: when therapeutic toxicity results from removing protein regulation, think oncogenes—these growth-promoting genes become dangerous when their normal controls are eliminated.

Question 12

Molecular analysis of paired tumor and normal tissue samples reveals distinct methylation patterns. In tumor samples, the promoter region of gene I shows hypermethylation and gene expression is silenced, while the promoter region of gene J shows hypomethylation and gene expression is increased 10-fold. Both changes are absent in corresponding normal tissues. Based on these epigenetic alterations, what can be concluded about genes I and J?

  1. Gene I is an oncogene silenced by tumor cells, while gene J is a tumor suppressor activated by tumor cells
  2. Gene I is a tumor suppressor silenced in tumors, while gene J is an oncogene activated in tumors (correct answer)
  3. Both genes are tumor suppressors that are dysregulated through different epigenetic mechanisms
  4. Both genes are oncogenes that are dysregulated through different epigenetic mechanisms
  5. Gene I and gene J represent reciprocally regulated genes in the same pathway
Explanation: When analyzing epigenetic changes in cancer, you need to understand how DNA methylation affects gene expression and what roles different gene types play in tumor development. Hypermethylation of promoter regions typically silences genes, while hypomethylation often leads to increased expression. Gene I shows hypermethylation and silencing in tumor cells. Since this gene is "turned off" in cancer, it likely serves a protective function that prevents tumor formation - making it a tumor suppressor. When tumor suppressors are silenced, cells lose important growth controls and can become cancerous. Gene J shows hypomethylation and 10-fold increased expression in tumors. This upregulation suggests the gene promotes cell growth or survival when overexpressed, which is characteristic of an oncogene. Oncogenes, when activated inappropriately, drive cancer development. This pattern points directly to answer B: Gene I is a tumor suppressor silenced in tumors, while gene J is an oncogene activated in tumors. Answer A incorrectly reverses the gene classifications - oncogenes aren't typically silenced in tumors, and tumor suppressors aren't activated. Answer C wrongly categorizes both as tumor suppressors, but gene J's overexpression pattern doesn't fit tumor suppressor behavior. Answer D incorrectly labels both as oncogenes, but gene I's silencing contradicts typical oncogene activation in cancer. Study tip: Remember the key pattern - in cancer, tumor suppressors get silenced (often through hypermethylation) while oncogenes get activated (often through hypomethylation or other mechanisms). The direction of expression change tells you the gene's likely function.

Question 13

A comparative proteomics study examines protein expression in cancer stem cells versus differentiated cancer cells from the same tumors. Gene O shows 20-fold higher expression in cancer stem cells, while gene P shows 15-fold higher expression in differentiated cancer cells. Functional studies reveal that forcing expression of gene O in differentiated cells increases their self-renewal capacity, while forcing expression of gene P in stem cells promotes their differentiation. How should genes O and P be classified in the context of cancer biology?

  1. Gene O is an oncogene that maintains cancer stemness, while gene P promotes differentiation (correct answer)
  2. Both genes are oncogenes that function in different cancer cell populations
  3. Gene O is a stemness tumor suppressor, while gene P is a differentiation oncogene
  4. Both genes are context-dependent regulators that cannot be clearly classified
  5. Gene O shows oncogenic properties by maintaining stemness, while gene P opposes tumorigenicity
Explanation: When analyzing cancer stem cell biology, you need to understand how gene expression patterns relate to cellular behavior and cancer progression. Cancer stem cells maintain self-renewal capacity and drive tumor growth, while differentiated cancer cells have limited proliferative potential. Gene O shows the classic profile of a stemness-maintaining oncogene. Its 20-fold higher expression in cancer stem cells, combined with its ability to increase self-renewal when forced into differentiated cells, demonstrates it actively promotes the dangerous stem-like properties that make cancers aggressive and treatment-resistant. This makes it an oncogene specifically functioning to maintain cancer stemness. Gene P shows opposite behavior - higher expression in differentiated cells and the ability to push stem cells toward differentiation. Since differentiation reduces the self-renewal capacity that makes cancer stem cells so dangerous, gene P actually opposes cancer progression by promoting a less harmful cell state. Looking at the wrong answers: B) incorrectly calls gene P an oncogene, but promoting differentiation actually reduces cancer aggressiveness, not increases it. C) misclassifies gene O as a tumor suppressor when it clearly promotes the harmful stemness phenotype, and incorrectly labels differentiation-promoting gene P as an oncogene. D) suggests the genes can't be classified, but their clear opposing functions in stemness versus differentiation make their roles quite definable. Study tip: In cancer biology questions, remember that stemness generally promotes cancer progression (oncogenic), while differentiation generally opposes it (tumor suppressive). Match gene function to cancer outcome, not just expression levels.

Question 14

A precision medicine approach analyzes tumor genomics to predict drug responses. Tumors with amplified gene U respond well to kinase inhibitors, while tumors with deleted gene U show poor response to the same drugs but respond well to DNA methyltransferase inhibitors. Conversely, tumors with deleted gene V respond well to kinase inhibitors, while tumors with amplified gene V show poor response to kinase inhibitors but respond well to proteasome inhibitors. What do these drug response patterns suggest about genes U and V?

  1. Both genes U and V are oncogenes with different therapeutic vulnerabilities
  2. Both genes U and V are tumor suppressors with different therapeutic approaches needed
  3. Gene U is an oncogene whose amplification creates kinase dependence, while gene V is a tumor suppressor whose loss creates kinase dependence (correct answer)
  4. Gene U is a tumor suppressor whose loss requires epigenetic therapy, while gene V is an oncogene whose amplification requires proteasome inhibition
  5. Genes U and V represent different therapeutic targets that require personalized treatment approaches
Explanation: When analyzing tumor genomics and drug responses, you need to distinguish between oncogenes (cancer-promoting genes) and tumor suppressors (cancer-preventing genes) based on how their amplification or deletion affects treatment sensitivity. For gene U, amplification creates responsiveness to kinase inhibitors, while deletion requires DNA methyltransferase inhibitors (epigenetic therapy). This pattern indicates gene U is an oncogene—when amplified, it drives oncogenic kinase signaling that can be targeted with kinase inhibitors. When deleted, the tumor develops through alternative pathways requiring epigenetic intervention. For gene V, the opposite occurs: deletion creates kinase inhibitor sensitivity, while amplification requires proteasome inhibitors. This suggests gene V is a tumor suppressor—when lost, tumors become dependent on kinase signaling for survival. When amplified, it likely creates protein stress requiring proteasome inhibition. Answer C correctly identifies this relationship: gene U as an oncogene whose amplification creates kinase dependence, and gene V as a tumor suppressor whose loss creates kinase dependence. Answer A incorrectly classifies both as oncogenes, missing gene V's tumor suppressor pattern. Answer B incorrectly labels both as tumor suppressors, ignoring gene U's oncogenic amplification pattern. Answer D reverses the gene classifications entirely—it misidentifies gene U as a tumor suppressor and gene V as an oncogene. Remember: oncogenes typically cause problems when amplified/overactive, while tumor suppressors cause problems when deleted/inactive. Match the drug response pattern to the underlying genetic mechanism.

Question 15

In a family with hereditary cancer syndrome, individuals inherit one defective copy of gene X. Cancer typically develops only after the remaining normal copy is lost through somatic mutation. In contrast, gene Y mutations are found in many tumors, but inheritance of mutant gene Y causes embryonic lethality. Which statement best explains the different inheritance patterns of these two cancer-related genes?

  1. Gene X is a tumor suppressor following Knudson's two-hit hypothesis, while gene Y is an oncogene essential for development (correct answer)
  2. Gene X is an oncogene with incomplete penetrance, while gene Y is a tumor suppressor with complete penetrance
  3. Both genes are tumor suppressors, but gene Y has additional essential functions during embryogenesis
  4. Gene X is a proto-oncogene that requires activation, while gene Y is a constitutively active oncogene
  5. Both genes are oncogenes, but gene X requires two hits for activation while gene Y is dominant
Explanation: This question tests your understanding of two fundamental classes of cancer genes and how they behave in inheritance patterns. When you see hereditary cancer syndromes described alongside embryonic lethality, think about the different roles genes play in both cancer and normal development. Gene X follows the classic pattern of a tumor suppressor gene described by Knudson's two-hit hypothesis. Individuals can survive with one defective copy because the remaining normal copy provides sufficient function. Cancer only develops when that second copy is lost through somatic mutation, removing all tumor suppressor activity. This explains why the hereditary syndrome exists—carriers are viable but predisposed to cancer. Gene Y represents an oncogene that's essential for development. When mutated and activated in somatic cells, oncogenes drive cancer formation. However, inheriting a mutant copy causes embryonic lethality because proper development requires precise control of these growth-promoting genes. A constitutively active or altered oncogene disrupts the carefully regulated developmental processes. Choice A correctly identifies this distinction. Choice B incorrectly classifies gene X as an oncogene—oncogenes don't follow two-hit patterns since they're dominant acting. Choice C mischaracterizes gene Y as a tumor suppressor, but tumor suppressors with developmental roles would cause problems when lost, not when inherited as mutants. Choice D wrongly calls gene X a proto-oncogene, which contradicts the two-hit inheritance pattern described. Remember: tumor suppressors follow two-hit patterns and can be inherited as single defective copies, while oncogenes essential for development cause embryonic lethality when inherited as mutants.

Question 16

In a chemical mutagenesis screen, researchers identify compounds that preferentially kill cancer cells over normal cells. Compound Alpha works by inhibiting protein M's kinase activity, while Compound Beta works by stabilizing protein N and preventing its degradation. Both compounds show selective toxicity for cancer cells. What do these different mechanisms of selective cancer cell killing suggest about proteins M and N?

  1. Protein M is a tumor suppressor kinase, while protein N is an oncogenic protein targeted for degradation
  2. Protein M is an oncogenic kinase that cancer cells depend on, while protein N is a tumor suppressor normally degraded in cancer (correct answer)
  3. Both proteins are oncogenes that cancer cells require for survival
  4. Both proteins are tumor suppressors that are dysregulated in cancer cells
  5. Protein M and protein N function in the same pathway but have opposite roles
Explanation: When analyzing cancer therapeutics, you need to understand how selective toxicity reveals the underlying biology of target proteins. The key insight is connecting each compound's mechanism to what cancer cells specifically depend on versus normal cells. Compound Alpha kills cancer cells by inhibiting protein M's kinase activity. This suggests protein M is something cancer cells rely on heavily - likely an oncogenic kinase that drives their survival and proliferation. Normal cells don't depend on this overactive kinase, so they survive the inhibition while cancer cells die. Compound Beta works by stabilizing protein N and preventing its degradation. This means protein N normally gets broken down in cancer cells, and restoring it kills them. This points to protein N being a tumor suppressor that cancer cells have learned to eliminate through enhanced degradation pathways. Looking at the wrong answers: Choice A reverses the logic - if protein M were a tumor suppressor kinase, inhibiting it would harm normal cells more than cancer cells. Choice C incorrectly categorizes protein N as an oncogene, but stabilizing an oncogene would promote cancer, not kill cancer cells. Choice D mischaracterizes protein M as a tumor suppressor, which contradicts why inhibiting it selectively harms cancer cells. The correct answer is B: protein M is an oncogenic kinase that cancer cells depend on (explaining why inhibiting it kills them), while protein N is a tumor suppressor that's normally degraded in cancer (explaining why stabilizing it restores tumor suppression). Study tip: In cancer biology questions, always ask whether restoring or blocking a protein would logically help or harm cancer cells to determine if it's oncogenic or tumor suppressive.

Question 17

Researchers develop a cellular transformation assay using normal human fibroblasts. When gene C is introduced with a strong promoter, cells become anchorage-independent and form colonies in soft agar. When gene D is introduced similarly, cells show enhanced contact inhibition and reduced growth rate. However, when both genes are introduced together, the cells show intermediate phenotype with some transformation characteristics. What does this combinatorial result suggest about genes C and D?

  1. Gene C is an oncogene and gene D is a tumor suppressor that partially antagonizes gene C's effects (correct answer)
  2. Both genes are oncogenes that function through different pathways
  3. Both genes are tumor suppressors with gene C showing dominant effects over gene D
  4. Gene C is a tumor suppressor and gene D is an oncogene that partially suppresses gene C's effects
  5. Genes C and D represent different phases of cell cycle control that must be balanced
Explanation: When analyzing cellular transformation assays, you need to understand how oncogenes and tumor suppressors affect normal cell behavior. Oncogenes promote cell division and transformation when overexpressed, while tumor suppressors normally prevent uncontrolled growth. Gene C's effects clearly indicate it's an oncogene: it causes anchorage-independent growth and soft agar colony formation, which are classic transformation characteristics. Normal cells require attachment to surfaces to survive and grow, so losing this requirement signals malignant transformation. Gene D shows tumor suppressor behavior: enhanced contact inhibition (cells stop dividing when they touch neighboring cells) and reduced growth rate are protective mechanisms that prevent cancer development. The key insight comes from the combinatorial result. When both genes are present, you see an intermediate phenotype with only "some transformation characteristics." This suggests gene D (tumor suppressor) partially counteracts gene C's (oncogene) transforming effects, but doesn't completely eliminate them. Answer A correctly identifies this relationship. Answer B is wrong because both genes aren't oncogenes—gene D clearly suppresses growth. Answer C incorrectly calls gene C a tumor suppressor when it clearly promotes transformation. Answer D reverses the gene identities—gene C promotes transformation (oncogene behavior) while gene D suppresses it. Remember: in transformation assays, look for the cellular behaviors each gene promotes. Oncogenes enable cancer-like properties (anchorage independence, reduced contact inhibition), while tumor suppressors enhance normal growth controls. The combinatorial effect reveals whether genes work together or antagonistically.

Question 18

In analyzing mutation patterns across different cancer types, researchers find that gene T shows point mutations clustered in its DNA-binding domain in some tumors, while showing complete deletions in other tumors. Functional studies reveal that the point mutations eliminate gene T's ability to bind DNA, while the deletions obviously eliminate protein production. Both mutation types correlate with increased tumor aggressiveness. What does this mutation pattern indicate about gene T's role in cancer?

  1. Gene T is an oncogene whose DNA-binding activity must be eliminated for tumor progression
  2. Gene T is a tumor suppressor whose DNA-binding function is essential for its protective role (correct answer)
  3. Gene T functions as both an oncogene and tumor suppressor depending on the type of mutation
  4. Gene T is a proto-oncogene that becomes activated when its DNA-binding domain is mutated
  5. Gene T is a cell cycle checkpoint gene whose function requires precise regulation
Explanation: When analyzing cancer gene mutations, pay attention to the pattern: mutations that eliminate function through different mechanisms (point mutations destroying activity vs. complete deletions) but produce the same cancer-promoting outcome typically indicate a tumor suppressor gene. Gene T shows a classic tumor suppressor mutation pattern. Both the DNA-binding domain point mutations and complete gene deletions eliminate the protein's normal protective function, and both correlate with increased tumor aggressiveness. This suggests that gene T normally acts as a "cellular brake" that prevents cancer progression through its DNA-binding activity. When this function is lost—whether through targeted mutations in the critical domain or wholesale gene deletion—the protective mechanism fails and tumors become more aggressive. Option A is incorrect because oncogenes promote cancer when they're activated or overexpressed, not when their activity is eliminated. Option C misses the point—having different mutation mechanisms doesn't mean the gene has dual roles; both mechanisms achieve the same functional outcome (loss of protective activity). Option D describes oncogene activation, but proto-oncogenes become cancer-promoting when mutated to gain function, not lose it. The correct answer is B because tumor suppressors are protective genes whose loss of function (through any mechanism) promotes cancer development. Study tip: Remember the "two-hit" concept for tumor suppressors—cancer cells find multiple ways to eliminate the same protective function. When you see different mutation types causing the same cancer-promoting outcome, think tumor suppressor, not oncogene.

Question 19

In a comparative study of tumor samples, gene M shows amplification (multiple copies) in 60% of tumors, while gene N shows deletion in 70% of tumors. When normal cells are transfected with multiple copies of gene M, they become tumorigenic. When normal cells are transfected with multiple copies of gene N, they show enhanced growth arrest responses to DNA damage. Based on these observations, which statement best describes the relationship between these genes and cancer development?

  1. Gene M is an oncogene activated by amplification, while gene N is a tumor suppressor inactivated by deletion (correct answer)
  2. Both genes are oncogenes, but gene M promotes proliferation while gene N promotes apoptosis resistance
  3. Both genes are tumor suppressors, but gene M is activated by amplification while gene N is inactivated by deletion
  4. Gene M is a tumor suppressor that becomes oncogenic when overexpressed, while gene N is a classical tumor suppressor
  5. Gene M and gene N represent complementary pathways that must both be disrupted for cancer development
Explanation: When analyzing genes in cancer, you need to distinguish between oncogenes (promote cancer when activated) and tumor suppressors (prevent cancer when functional). The key clues are how the genes behave when altered and what happens during transfection experiments. Gene M shows amplification in tumors and causes normal cells to become tumorigenic when overexpressed - this is classic oncogene behavior. Oncogenes drive cancer when they gain function through mechanisms like amplification. Gene N shows deletion in tumors and enhances growth arrest (a protective response) when overexpressed - this indicates tumor suppressor function. Tumor suppressors prevent cancer when functional, so they're typically lost or deleted in tumors. Choice A correctly identifies gene M as an oncogene activated by amplification and gene N as a tumor suppressor inactivated by deletion. Choice B incorrectly classifies gene N as an oncogene - but oncogenes wouldn't be deleted in tumors, and enhancing growth arrest opposes cancer development. Choice C misclassifies gene M as a tumor suppressor - tumor suppressors don't cause normal cells to become tumorigenic when overexpressed. Choice D suggests gene M is a tumor suppressor that becomes oncogenic, but this contradicts the amplification pattern seen in tumors and the tumorigenic effect of overexpression. Remember: oncogenes are typically amplified/overexpressed in cancer and promote tumorigenesis when activated, while tumor suppressors are typically deleted/inactivated in cancer and protect against tumorigenesis when functional. The transfection results reveal each gene's normal cellular role.